Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia.
about
Acute lymphoblastic leukaemiaChildhood Acute Lymphoblastic Leukemia: Progress Through CollaborationGenome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemiaMinimally-Myelosuppressive Asparaginase-Containing Induction Regimen for Treatment of a Jehovah's Witness with mutant IDH1/NPM1/NRAS Acute Myeloid LeukemiaGenetics of ancestry-specific risk for relapse in acute lymphoblastic leukemiaRationale for a pediatric-inspired approach in the adolescent and young adult population with acute lymphoblastic leukemia, with a focus on asparaginase treatment.Metabolomics of the tumor microenvironment in pediatric acute lymphoblastic leukemia.Effect of premedications in a murine model of asparaginase hypersensitivityEnergy balance and fitness in adult survivors of childhood acute lymphoblastic leukemia.Inherited genetic variation in childhood acute lymphoblastic leukemia.Genome-wide analysis links NFATC2 with asparaginase hypersensitivity.Asparaginase Potentiates Glucocorticoid-Induced Osteonecrosis in a Mouse ModelPediatric acute lymphoblastic leukemia: where are we going and how do we get there?Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia.Is Erwinase Necessary for all Children With ALL and Allergic Reactions to E. coli Asparaginase?Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer InstitutA 50-year journey to cure childhood acute lymphoblastic leukemiaA prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia.Erwinia asparaginase in pediatric acute lymphoblastic leukemia.Incidence, clinical features and management of hypersensitivity reactions to chemotherapeutic drugs in children with cancer.Update on the Use of l-Asparaginase in Infants and Adolescent Patients with Acute Lymphoblastic Leukemia.Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia.Personalization of dexamethasone therapy in childhood acute lymphoblastic leukaemia.Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients.Immunology of infusion reactions in the treatment of patients with acute lymphoblastic leukemia.Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia.Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951.Outcomes Following Discontinuation of E. coli l-Asparaginase Upon Severe Allergic Reactions in Children With Acute Lymphoblastic Leukemia.Do immunoglobulin G and immunoglobulin E anti-l-asparaginase antibodies have distinct implications in children with acute lymphoblastic leukemia? A cross-sectional studyAn investigation of toxicities and survival in Hispanic children and adolescents with ALL: Results from the Dana-Farber Cancer Institute ALL Consortium protocol 05-001.Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia.Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation.A retrospective comparison of Escherichia coli and polyethylene glycol-conjugated asparaginase for the treatment of adolescents and adults with newly diagnosed acute lymphoblastic leukemia.A novel chemosensitivity profiling platform for small acute lymphoblastic leukemia cell populations.
P2860
Q24602387-EE5378A6-23C7-44C8-8C34-41EC2086F2E8Q28087637-BF59E6EE-B375-40C3-B98C-8B30103A0634Q28943431-E9CCD44D-5AE3-4792-93F1-4B22AD8D4607Q33431399-B7DC9FDE-286C-4134-9B66-818942FFAFA6Q33774499-0D4B37EC-2C9B-41C7-BE74-2090C7D7B740Q34325815-432BFC01-3928-4F56-A9AB-B16B68822049Q35070594-FD3FB469-6759-4B45-8D9A-CB5034E620E2Q35156439-F9ED3221-3CE7-4FE0-9E55-20044E7D63C2Q35661991-295F6F4C-59F1-4265-914A-CFD2BB7E1C18Q35784497-B31A6B12-0FA2-491F-8815-B63FAE5219ABQ35820373-2E44DC10-5DF9-44D0-89DC-3D38C0FD1137Q35954058-E62C2233-DE02-4C00-8E77-46A3A4BD6786Q36163029-D2DEB2B9-5751-43DD-9B11-07B58CFC7F12Q36452241-4119DB64-00CB-4464-9FEB-B1620BA93089Q36586248-A6294085-4EA7-42CF-8D6C-8BF75B9EF499Q36678136-15A51725-082F-45E6-B17A-A0314D83AEF6Q37166753-14D77496-CEAE-4C23-8D4B-0719F3A17E0FQ37670065-F3F67C62-0E3B-43E9-B575-E82C7398513EQ38040418-CDD89474-90BD-4FE8-AA02-93939CF42BBAQ38114361-84EB8558-132E-4B01-AB95-979B813FCDD7Q38248280-94EFAF69-8BD9-49EF-BF66-C2D6C4CDA1C1Q38289596-16ED6F2B-1DFA-4262-8667-CB751F56335BQ38686308-08339030-7CCB-4F1A-B25B-0959817EFBC2Q38748699-9983A12B-5315-44C6-B995-96785DCA836FQ38880102-39BA6234-72B2-4397-84D1-036C83211D74Q38933372-FB75B6CA-C57F-4CAB-8C4F-83148556540FQ40116316-2B8BD318-95B2-4130-92A7-C8DA43E04F34Q41021920-E3DC1276-8F26-44D7-AD3D-50F756A57960Q41491082-25EADA45-62D5-460C-8D5E-C9F24E72605AQ45071531-023956BD-D5FE-4EB7-8451-5EC461F9FFD2Q48166631-B0AC1EA0-9217-4CF0-8EA1-5826DD2B428EQ48203946-95B969E7-9A2C-48ED-9496-0E22A1E5A72AQ49412789-F9FFF51C-11C4-4FCC-982B-DDA4A6F5E5BFQ53662426-60DFBE16-35C4-4CBE-A8E8-D71F1E8EA9B2
P2860
Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Dexamethasone exposure and asp ...... acute lymphoblastic leukemia.
@ast
Dexamethasone exposure and asp ...... acute lymphoblastic leukemia.
@en
type
label
Dexamethasone exposure and asp ...... acute lymphoblastic leukemia.
@ast
Dexamethasone exposure and asp ...... acute lymphoblastic leukemia.
@en
prefLabel
Dexamethasone exposure and asp ...... acute lymphoblastic leukemia.
@ast
Dexamethasone exposure and asp ...... acute lymphoblastic leukemia.
@en
P2093
P2860
P1433
P1476
Dexamethasone exposure and asp ...... acute lymphoblastic leukemia.
@en
P2093
Cheng Cheng
Chengcheng Liu
Christian A Fernandez
Dario Campana
Deqing Pei
Jitesh D Kawedia
John C Panetta
Mary V Relling
Scott C Howard
W Paul Bowman
P2860
P304
P356
10.1182/BLOOD-2011-09-381731
P407
P577
2011-11-23T00:00:00Z